Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 24Paclitaxel 7Docetaxel 7Cyclophosphamide 7Carboplatin 7fludarabine 6Taxes 6Nivolumab 6Trastuzumab 5Magnetic Resonance Spectroscopy 5atezolizumab 4Specimen Handling 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Gemcitabine 4Fluorouracil 4Cisplatin 4tisotumab vedotin 3fludarabine phosphate 3Radiation 3Oxaliplatin 3Leucovorin 3Irinotecan 3Ipilimumab 3Gene Expression Profiling 3Drug Therapy 3Counseling 3Albumin-Bound Paclitaxel 3zimberelimab 2ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × CLR1404 × Gynecologic × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡